Trinity Capital Inc., a leading international alternative asset manager, today announced the commitment of $30 million in growth capital to Iantrek, a medical technology company and a leader in the bio-interventional ophthalmic surgery (BIOS) space.
Iantrek develops minimally invasive surgical technologies designed to treat chronic eye diseases, particularly glaucoma, aimed at restoring the eye’s natural fluid outflow pathways and reducing ocular pressure. Its technology includes instrumentation and biologic tissue solutions that seek to help enable micro-interventional procedures for improved patient outcomes.
Related: Hypervision raises $23M Series A for hyperspectral surgical imaging tech
“We believe Iantrek’s innovative technology, strong clinical evidence, and early commercialization results position them well to be a leader in surgical ophthalmology,” said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital. “We are pleased to support their team as they enter this next phase of rapid growth.”
This debt facility follows a successful series C raise in 2025 which closed in 2025 and included lead equity investors USVP, Sectoral, aMoon, and Visionary Ventures. Trinity’s growth capital will support Iantrek in accelerating commercial expansion of its product portfolio, advancing development and regulatory activities for pipeline products, scaling manufacturing and distribution capabilities, and strengthening market access initiatives to broaden physician and patient adoption.
“This financing is a strategic step to keep pace with growing physician demand for our platform. It positions us to accelerate adoption of AlloFlo Uveo, our lead commercial technology, and advance the next wave of bio-interventional innovation,” said Adam Szaronos, Chief Executive Officer of Iantrek.
